Trial Profile

A Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in People Who Inject Drugs and People With HIV Coinfection.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jul 2023 Results assessing incidence of, and factors associated with reinfection among people treated for recent HCV , published in the AIDS
20 May 2021 Primary endpoint (The proportion of participants with undetectable HCV RNA at 12 weeks post end of treatment following SOF/VEL for 6 weeks as compared with 12 weeks in people with recent HCV infection (duration of infection less than or equal to 12 months)) has not been met, according results published in the Journal of Hepatology.
20 May 2021 Results assessing to compare the efficacy and safety of sofosbuvir/velpatasvir administered for 6 or 12 weeks in individuals with recent HCV infection, published in the Journal of Hepatology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com